XVIVO PERFUSION AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 515 SEK | +23.80% |
|
+27.00% | +56.30% |
| Jul. 12 | Transcript : Xvivo Perfusion AB, Q2 2024 Earnings Call, Jul 12, 2024 | |
| Jul. 12 | Xvivo Perfusion AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 | CI |
Presentation Operator MessageOperator (Operator)Welcome to Xvivo Q2 Report for 2024. [Operator...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Companyâs product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
Calendar
2024-10-24
- Q3 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
515
SEK
Average target price
450
SEK
Spread / Average Target
-12.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +56.30% | 1.54B | |
| -5.31% | 181B | |
| -5.38% | 99.95B | |
| -6.04% | 66.21B | |
| +16.45% | 45.4B | |
| -8.08% | 45.36B | |
| +8.38% | 43.84B | |
| +12.06% | 29.03B | |
| +17.98% | 25.64B | |
| -8.28% | 23.53B |
- Stock Market
- Equities
- XVIVO Stock
- News Xvivo Perfusion AB
- Transcript : Xvivo Perfusion AB, Q2 2024 Earnings Call, Jul 12, 2024
